Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study by Jenkins, Christine R et al.
BioMed  Central
Page 1 of 9
(page number not for citation purposes)
Respiratory Research
Open Access Research
Efficacy of salmeterol/fluticasone propionate by GOLD stage of 
chronic obstructive pulmonary disease: analysis from the 
randomised, placebo-controlled TORCH study
Christine R Jenkins*†1, Paul W Jones†2, Peter MA Calverley†3, 
Bartolome Celli†4, Julie A Anderson†5, Gary T Ferguson†6, Julie C Yates†7, 
Lisa R Willits†5 and Jörgen Vestbo†8,9
Address: 1Woolcock Institute of Medical Research, Sydney, Australia, 2Division of Cardiac and Vascular Science, St George's, University of London, 
London, UK, 3University Hospital, Liverpool, UK, 4St Elizabeth's Medical Centre, Boston, USA, 5GlaxoSmithKline (GSK), Stockley Park, UK, 
6Pulmonary Research Institute of Southeast Michigan, Livonia, USA, 7GSK, Research Triangle Park, USA, 8Wythenshawe Hospital, Manchester, UK 
and 9Hvidovre Hospital, Hvidovre, Denmark
Email: Christine R Jenkins* - crj@med.usyd.edu.au; Paul W Jones - pjones@sgul.ac.uk; Peter MA Calverley - pmacal@liv.ac.uk; 
Bartolome Celli - bcelli@semc.org; Julie A Anderson - julie.a.anderson@gsk.com; Gary T Ferguson - garytferguson@msn.com; 
Julie C Yates - julie.c.yates@gsk.com; Lisa R Willits - lisa.r.willits@gsk.com; Jörgen Vestbo - jvestbo@man.ac.uk
* Corresponding author    †Equal contributors
Abstract
Background: The efficacy of inhaled salmeterol plus fluticasone propionate (SFC) in patients with
severe or very severe COPD is well documented. However, there are only limited data about the
influence of GOLD severity staging on the effectiveness of SFC, particularly in patients with milder
disease.
Methods: TORCH was a 3-year, double-blind, placebo-controlled trial of 6112 patients with
moderate/severe COPD with pre-bronchodilator FEV1 < 60% predicted (mean age 65 years, 76%
male, mean 44% predicted FEV1, 43% current smokers). To understand the relative efficacy of SFC
and its components by GOLD stages, we conducted a post-hoc analysis of the TORCH dataset
using baseline post-bronchodilator FEV1 to segment patients into three groups: moderate COPD
(GOLD stage II and above: ³ 50%; n = 2156), severe COPD (GOLD stage III: 30% to < 50%; n =
3019) and very severe COPD (GOLD stage IV: < 30%; n = 937).
Results:  Compared with placebo, SFC improved post-bronchodilator FEV1: 101 ml (95%
confidence interval [CI]: 71, 132) in GOLD stage II, 82 ml (95% CI: 60, 104) in GOLD stage III and
96 ml (95% CI: 54, 138) in GOLD stage IV patients, and reduced the rate of exacerbations: 31%
(95% CI: 19, 40) in GOLD stage II, 26% (95% CI: 17, 34) in GOLD stage III and 14% (95% CI: -4,
29) in GOLD stage IV. SFC improved health status to a greater extent than other treatments
regardless of baseline GOLD stage. Similarly, SFC reduced the risk of death by 33% (hazard ratio
[HR] 0.67; 95% CI: 0.45, 0.98) for GOLD stage II, 5% (HR 0.95; 95% CI: 0.73, 1.24) for GOLD stage
III, and 30% (HR 0.70; 95% CI: 0.47, 1.05) for GOLD stage IV. The rates of adverse events were
similar across treatment arms and increased with disease severity. Overall, there was a higher
incidence of pneumonia in the fluticasone propionate and SFC arms, compared with other
treatments in all GOLD stages.
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Conclusion: In the TORCH study, SFC reduced moderate-to-severe exacerbations and improved
health status and FEV1 across GOLD stages. Treatment with SFC may be associated with reduced
mortality compared with placebo in patients with GOLD stage II disease. The effects were similar
to those reported for the study as a whole. Thus, SFC is an effective treatment option for patients
with GOLD stage II COPD.
Trial registration: Clinicaltrial.gov registration NCT00268216; Study number: SCO30003
Background
The last decade has seen a series of randomized controlled
trials (RCTs) of pharmacological treatment which have
provided a strong evidence base for the role of drug treat-
ment in the management of chronic obstructive pulmo-
nary disease (COPD) [1]. The efficacy of inhaled
corticosteroid/long-acting  b-agonist (ICS/LABA) combi-
nations, including the salmeterol/fluticasone propionate
combination (SFC), in COPD has been clearly shown for
many clinically relevant outcomes including exacerbation
frequency, rate of lung function decline and health status
in patients with severe and very severe COPD (GOLD
stages III and IV) [2-4]. To date there has been a paucity of
information about the effectiveness of these agents in
patients with GOLD stage II COPD, with the robustness of
any clinical conclusions drawn being limited by the rela-
tively small size of the subgroups reported [5].
Previous RCTs examining treatment effects with these
drugs recruited patients entirely or predominantly from
GOLD stages III and IV [6-9]. These data contributed to
COPD treatment guidelines recommending the use of
ICS/LABA combinations to reduce the frequency and
severity of exacerbations and improving lung function
and health status in patients with more severe COPD
(forced expiratory volume in one second [FEV1] < 50%
predicted) and a history of exacerbations. The absence of
RCT data applicable to patients with GOLD stage II COPD
can now be redressed through analysis of the results in
patients with milder disease in recent large trials [2,10].
The TORCH study is the largest trial of pharmacotherapy
ever undertaken in COPD. It randomized over 6000
patients, and investigated the effects of SFC, salmeterol
(SAL), fluticasone propionate (FP) and placebo on mor-
tality, lung function, exacerbations and quality of life in
patients with COPD. The study included patients with a
pre-bronchodilator FEV1 of less than 60% predicted irre-
spective of their prior exacerbation history [11]. As GOLD
stages of severity are defined by the post-bronchodilator
FEV1, a substantial proportion of TORCH participants had
GOLD stage II disease. The TORCH data therefore provide
a unique opportunity to analyse the clinical efficacy and
adverse events (AEs) profile of SFC and its components
(SAL and FP) in patients at different stages of COPD. In
this post-hoc analysis we have focussed on the effects of
SFC on mortality, exacerbations, lung function and qual-
ity of life by GOLD stage, with particular emphasis on
patients with diagnosed GOLD stage II disease.
Methods
Full details of the TORCH methodology have been pub-
lished previously [2,11].
Patients
Current or former smokers with at least a 10-pack-year
history, aged between 40 and 80 years, with a confirmed
diagnosis of COPD and pre-bronchodilator FEV1 less than
60% of the predicted value were enrolled in the TORCH
study. In addition, patients were required to show less
than 10% reversibility (as a percentage of predicted FEV1)
to 400 mg salbutamol and a FEV1/forced vital capacity
(FVC) ratio of 0.70 or less. Patients were excluded if they
had a diagnosis of asthma or other non-COPD respiratory
disorder, any other condition likely to cause death within
3 years, previous lung volume reduction surgery and/or
lung transplantation, a requirement for oxygen therapy
for at least 12 hours per day, current use of oral corticos-
teroid therapy, or experienced an exacerbation requiring
systemic oral corticosteroid therapy and/or hospitaliza-
tion during the run-in period. All patients gave written
informed consent. The study was approved by local ethics
review committees and was conducted in accordance with
the Declaration of Helsinki and Good Clinical Practice
guidelines.
Study design
The TORCH study design has been described in detail in
previous publications [2,11]. Briefly, 6112 patients at 439
centres in 42 countries were included in the efficacy anal-
yses and 6184 patients at 444 centres were included in the
safety analyses. Patients were randomized using a double-
blind parallel group design to receive twice-daily adminis-
tration of SAL 50 mg, FP 500 mg, SFC 50 mg/500 mg, or pla-
cebo for 3 years. The primary efficacy outcome was all-
cause mortality over 3 years, regardless of whether
patients withdrew from the study early. Secondary out-
comes were exacerbation rate, health status, lung function
and AEs while on treatment.Respiratory Research 2009, 10:59 http://respiratory-research.com/content/10/1/59
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GOLD stage analysis
For this post-hoc analysis, baseline post-bronchodilator
FEV1 was used to group patients into GOLD-stage catego-
ries. At baseline, the highest of three acceptable measure-
ments of FEV1 was recorded 30 minutes after inhalation of
400 mg salbutamol via metered-dose inhaler and Volu-
matic spacer (ELLIPSE at US centres). The GOLD stages
are categorized as follows: stage II corresponds to post-
bronchodilator FEV1 50% to < 80% predicted, stage III to
30% to < 50% predicted, and stage IV to < 30% predicted
[1]. In this post-hoc analysis of TORCH, the GOLD stage
II category included 28 patients (five, two, nine and 12 in
the placebo, SAL, FP and SFC treatment arms, respec-
tively) with a post-bronchodilator FEV1 ³ 80% (GOLD
stage I).
Statistical analysis
Time to all-cause mortality was analyzed using the log-
rank test, stratified by smoking status. Exacerbation rates
were analyzed using a generalized linear model (assuming
the Negative Binomial distribution, to account for patient
variability), adjusted for age, gender, body mass index
(BMI), baseline FEV1, previous exacerbations, region and
smoking status. Quality of life was determined using the
St George's Respiratory Questionnaire (SGRQ). Total
SGRQ scores were analyzed as changes from baseline val-
ues using repeated measures analysis of covariance
(ANCOVA), using the covariates age, gender, BMI, base-
line FEV1, baseline SGRQ, region and smoking status.
Post-bronchodilator FEV1 was analyzed using repeated
measures ANCOVA with covariates of age, gender, BMI,
baseline FEV1, region and smoking status. The rate of
decline in FEV1 was analyzed using a random coefficients
model adjusted for the same covariates, with random
patient effects. AEs and serious AEs (SAEs) were coded
using the Medical Dictionary for Regulatory Affairs (Med-
DRA, version 8.1) and summarized by treatment arm.
Time to first pneumonia analyzed using the log-rank test,
stratified by smoking status and was compared across
treatment arms using Kaplan-Meier estimates. Pneumonia
rates were expressed as per 1000 treatment years, by divid-
ing the total number of events by the total time on treat-
ment in years, then multiplying by 1000.
To determine whether the treatment effects were consist-
ent across severity groups, the interaction of treatment by
severity group was tested for each endpoint.
Results
Demographics
Baseline characteristics were similar across groups when
stratified by GOLD stage (Table 1). The main differences
between the groups were that the GOLD stage IV group
had a higher proportion of males (83% versus 76% and
72% in the GOLD stage III and II groups), contained more
former smokers (66% versus 57% and 53% in the GOLD
stage III and II groups) and experienced more exacerba-
tions requiring oral corticosteroids or antibiotics in the
year prior to the study (mean of 1.3 versus 1.0 and 0.9 in
the GOLD stage III and II groups). Baseline SGRQ total
scores were higher with increasing disease severity,
defined spirometrically. Mean reversibility within each
GOLD stage was less than 5% of the predicted FEV1 (Table
1). A total of 16 patients violated the entry criteria and had
reversibility 10–15% (six on placebo, three on SAL, six on
FP and one on SFC). Of patients categorized as GOLD
Table 1: Demographic and baseline characteristics by GOLD stage*
Variable Stage IV
(< 30% predicted)
(n = 937)
Stage III
(30% to < 50% predicted)
(n = 3019)
Stage II
(³ 50% predicted)
(n = 2156)
Total population
(n = 6112)
age, mean (years) 64.2 ± 7.8 65.4 ± 8.1 64.9 ± 8.7 65.0 ± 8.3
male (%) 83 76 72 76
BMI, mean (kg/m2) 23.5 ± 4.9 25.1 ± 5.0 26.6 ± 5.2 25.4 ± 5.2
smoking status: current (%) 34 43 47 43
exacerbations
number requiring antibiotics and/or oral 
corticosteroids, mean
1.3 ± 1.5 1.0 ± 1.4 0.9 ± 1.2 1.0 ± 1.3
number requiring hospitalization, mean 0.4 ± 0.7 0.3 ± 0.7 0.2 ± 0.5 0.2 ± 0.6
post-bronchodilator FEV1, mean (ml) 704 ± 160 1108 ± 263 1616 ± 399 1226 ± 443
% predicted post-bronchodilator FEV1, mean 24.6 ± 4.0 40.1 ± 5.7 58.8 ± 7.4 44.3 ± 13.4
SGRQ score, mean (n = 730) (n = 2460) (n = 1761) (n = 4951)
total score 56.5 ± 15.0 50.0 ± 16.5 45.4 ± 17.7 49.3 ± 17.1
symptoms score 67.0 ± 18.0 63.5 ± 19.3 60.3 ± 21.0 62.9 ± 19.9
activity score 73.4 ± 16.7 64.1 ± 19.0 57.1 ± 20.6 63.0 ± 20.0
impact score 43.6 ± 18.6 37.7 ± 18.8 33.6 ± 19.6 37.1 ± 19.3
reversibility as % of predicted FEV1, mean 2.5 ± 3.2 3.6 ± 3.6 4.3 ± 4.0 3.7 ± 3.7
*Plus-minus values are mean ± standard deviationRespiratory Research 2009, 10:59 http://respiratory-research.com/content/10/1/59
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stage II, most had post-bronchodilator FEV1 at baseline of
50% to < 60%, however there were 796 patients (37%)
with FEV1 ³ 60% (Table 2).
Withdrawal
Increasing severity by GOLD staging was associated with a
higher probability of withdrawal over the 3-year study.
More patients withdrew in the placebo arm compared
with the SFC arm in all severity stages, and the lowest rate
of withdrawals across all treatments was in patients in
GOLD stage II (Figure 1).
Mortality
In GOLD stage II, the risk of death was reduced by 33%
(HR 0.67; 95% CI: 0.45, 0.98; 11.4% of the patients died
on placebo compared with 7.8% on SFC). The absolute
risk reduction was 3.6%. The risk of death was reduced by
5% (HR 0.95; 95% CI: 0.73, 1.24) in GOLD stage III
patients and by 30% (HR 0.70; 95% CI: 0.47, 1.05) in
GOLD stage IV patients (Figure 2).
The effects of SAL and FP on the probability of death ver-
sus placebo or SFC were generally similar across GOLD
stages (Figure 2).
Moderate/severe exacerbation rates
SFC reduced the annual rate of exacerbations by 31% (CI:
19, 40) compared with placebo (mean of 0.57/year in SFC
versus 0.82/year in placebo) in patients with GOLD stage
II COPD. Patients with GOLD stage III and IV COPD also
experienced a reduction in exacerbations. Compared with
placebo, SFC reduced the number of exacerbations in
patients with GOLD stage III COPD by 26% (CI: 17, 34)
per year (mean of 0.91/year for SFC versus 1.24/year for
placebo). In patients with GOLD stage IV COPD, SFC
reduced exacerbations by 14% (CI: -4, 29) per year versus
placebo (mean of 1.54/year for SFC versus 1.79/year for
placebo) (Figure 3).
FEV1
Improvements in FEV1 with SFC versus placebo were 101
ml (95% CI: 71, 132) in GOLD stage II patients, 82 ml
(95% CI: 60, 104) in GOLD stage III patients and 96 ml
(95% CI: 54, 138) in GOLD stage IV patients (Figure 4).
The reduction in the rate of decline in FEV1 with SFC ver-
sus placebo was 16 ml/year (95% CI: 0, 32) in GOLD
stage II patients, 16 ml/year (95% CI: 5, 28) in GOLD
stage III patients and 11 ml/year (95% CI: -8, 30) in
GOLD stage IV patients (Figure 5).
Health status
The greatest improvement relative to placebo was
observed in those patients with more severe disease
treated with SFC (Figure 6). The difference in adjusted
mean change in SGRQ for SFC versus placebo was -2.3
(95% CI: -4.0, -0.7) in GOLD stage II, -3.3 (95% CI: -4.7,
-1.9) in GOLD stage III and -5.9 (95% CI: -8.7, -3.0) in
GOLD stage IV. A numerical trend to greater improvement
in SGRQ with worsening GOLD stage was noted with all
active treatments, however this was not statistically signif-
icant.
Treatment interaction
There was no evidence of a difference in treatment effect
across the GOLD stages on all-cause mortality (p = 0.402
for the interaction test), exacerbations (p = 0.254), post-
bronchodilator FEV1 (p = 0.298), rate of decline in FEV1 (p
= 0.830) or SGRQ (p = 0.321).
Safety
Consistent with the results from the original analysis, the
incidence of any AE was similar across the treatment arms,
irrespective of GOLD stage. The incidence of SAEs and
fatal AEs was also similar across treatment arms, and
increased with increasing disease severity (Table 3). The
most frequently reported AE, irrespective of GOLD stage,
was an exacerbation of COPD.
The incidence of pneumonia increased with disease sever-
ity, irrespective of treatment. The probability of pneumo-
nia as an AE was increased in patients receiving ICS-
containing therapy (SFC, FP) compared with those
patients not receiving ICS (SAL, placebo) in all GOLD
stages (Table 4; Figure 7). When investigating treatment
interactions for time to first pneumonia, there was no evi-
dence of treatment differences across GOLD stages (p =
0.402).
Table 2: Post-bronchodilator FEV1 % predicted at baseline
FEV1, % predicted, n (%) placebo
(n = 1524)
SAL
(n = 1521)
FP
(n = 1534)
SFC
(n = 1533)
total
(n = 6112)
< 30% 214 (14) 260 (17) 220 (14) 243 (16) 937 (15)
30% to < 50% 775 (51) 739 (49) 777 (51) 728 (47) 3019 (49)
50% to < 60% 347 (23) 335 (22) 329 (21) 349 (23) 1360 (22)
60% to < 70% 148 (10) 160 (11) 165 (11) 173 (11) 646 (11)
70% to < 80% 35 (2) 25 (2) 34 (2) 28 (2) 122 (2)
³ 80% 5 (< 1) 2 (< 1) 9 (< 1) 12 (< 1) 28 (< 1)Respiratory Research 2009, 10:59 http://respiratory-research.com/content/10/1/59
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Discussion
Large prospective randomized clinical trials are designed
to report their pre-specified outcomes in the recruited
population. However, clinicians are also interested in
whether treatment responses vary within specific subsets
of patients which, in the case of COPD, have been defined
in terms of the post-bronchodilator FEV1 thresholds used
in the GOLD guidelines. Indeed guidelines require this
type of post-hoc analysis since they encourage more tar-
geted therapy to specific patient groups. Based on the size
of studies like TORCH and UPLIFT [10], there is reasona-
ble power to conduct exploratory post-hoc analysis of sec-
ondary outcomes. In the case of TORCH, where
approximately one-third of the TORCH study population
fell into the GOLD stage II category, the present post-hoc
analysis demonstrates that SFC improved SGRQ, reduced
exacerbations and improved lung function when com-
pared with placebo. SFC was also associated with reduced
mortality in GOLD stage II patients, compared with pla-
cebo.
TORCH recruited patients with a history of COPD, revers-
ibility to salbutamol of < 10% of predicted FEV1 and
excluded patients with a diagnosis of asthma. Reversibility
to bronchodilation has been shown to be variable within
COPD patients and the presence or absence of reversibil-
ity on a single test is not an important criterion to predict
response to ICS [12]. A very small number of patients in
TORCH (16 patients) were protocol violators on the
reversibility entry criterion.
The primary purpose of the TORCH trial was to determine
whether SFC reduced all-cause mortality compared with
placebo treatment (effectively regular short-acting bron-
Rate of withdrawal of patients over the 3-years duration of  the study by baseline post-bronchodilator FEV1 % predicted Figure 1
Rate of withdrawal of patients over the 3-years dura-
tion of the study by baseline post-bronchodilator 
FEV1 % predicted.
All-cause mortality by baseline post-bronchodilator FEV1 %  predicted Figure 2
All-cause mortality by baseline post-bronchodilator 
FEV1 % predicted.
Exacerbation rate by baseline post-bronchodilator FEV1 %  predicted Figure 3
Exacerbation rate by baseline post-bronchodilator 
FEV1 % predicted.
Adjusted mean FEV1 over 3 years by baseline post-bron- chodilator FEV1 % predicted Figure 4
Adjusted mean FEV1 over 3 years by baseline post-
bronchodilator FEV1 % predicted.Respiratory Research 2009, 10:59 http://respiratory-research.com/content/10/1/59
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chodilator therapy). As discussed elsewhere [2], TORCH
was probably underpowered to show this difference in a
4-arm study design and so particular caution is needed
when interpreting mortality data between GOLD stage
subgroups in this post-hoc analysis. However, while
patients showed an increased risk of dying as their base-
line spirometry worsened, there was a lower mortality
with SFC treatment even in those with GOLD stage II dis-
ease. Clearly this finding should be confirmed by further
prospective studies.
As expected, the burden of disease increased with severity
regardless of the endpoint measured (mortality, exacerba-
tions, FEV1, and AEs). All subgroup analyses should be
treated with caution. However, treatment to prevent exac-
erbations seemed just as effective whatever the GOLD
stage. The exacerbation frequency on placebo was lowest
in GOLD stage II, but was not negligible with a rate of
0.82 events per year. We observed the same proportionate
reduction in events with SFC therapy in GOLD stage II
patients suggesting that treatment would be worthwhile
for these patients. Deterioration in health status was seen
over 3 years in the placebo arm in patients with GOLD
stages III and IV, but those in GOLD II showed a small
improvement. SFC improved health status by approxi-
mately the same amount from baseline in all three GOLD
stages. In patients with more severe disease, the main
effect of SFC appears to be to slow the rate of progression
relative to placebo. However, it is clear that patients in
GOLD stage II do have better health status when treated
with SFC compared with placebo, with a change of over
two units in total score maintained over the 3 years of
study.
Table 3: Incidence of adverse events by post bronchodilator % predicted FEV1*
Variable Placebo
(n = 1544)
SAL
(n = 1542)
FP
(n = 1552)
SFC
(n = 1546)
FEV1 < 30% predicted
n 215 261 223 246
any AE, n (%) 198 (92) 241 (92) 212 (95) 230 (93)
serious AEs, n (%) 108 (50) 142 (54) 129 (58) 134 (54)
fatal AEs, n (%) 26 (12) 35 (13) 35 (16) 25 (10)
FEV1 30% to < 50% predicted
n 786 750 785 735
any AE, n (%) 717 (91) 669 (89) 702 (89) 664 (90)
serious AEs, n (%) 322 (41) 306 (41) 357 (45) 327 (44)
fatal AEs, n (%) 70 (9) 62 (8) 87 (11) 62 (8)
FEV1 ³ 50% predicted
n 543 531 544 565
any AE, n (%) 470 (87) 471 (89) 481 (88) 487 (86)
serious AEs, n (%) 197 (36) 174 (33) 169 (31) 198 (35)
fatal AEs, n (%) 37 (7) 29 (5) 38 (7) 27 (5)
*Safety population (n = 6184)
Rate of decline in FEV1 by baseline post-bronchodilator FEV1  % predicted Figure 5
Rate of decline in FEV1 by baseline post-bronchodila-
tor FEV1 % predicted.
Improvement (reduction) in SGRQ vs placebo by baseline  post-bronchodilator FEV1 % predicted Figure 6
Improvement (reduction) in SGRQ vs placebo by 
baseline post-bronchodilator FEV1 % predicted.Respiratory Research 2009, 10:59 http://respiratory-research.com/content/10/1/59
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The treatment effects on post-bronchodilator FEV1 fol-
lowed a similar pattern across all GOLD stages. The rate of
decline in FEV1 tended to be slightly lower in GOLD stage
IV than in stage II. SFC reduced the rate of FEV1 decline by
16 ml/year versus placebo in GOLD stage II patients ver-
sus 11 ml/year in stage IV patients which is comparable to
the result reported in the overall population [13].
In our study, the incidence and severity of AEs was gener-
ally comparable across treatment arms, regardless of
GOLD stage. Increased incidence of pneumonia has previ-
ously been reported with the use of ICS-containing ther-
apy [2] and whilst this was observed, the probability of
pneumonia with SFC in GOLD stage II patients was lower
than that observed in the overall population. Further
study is required however, to determine the exact mecha-
nisms involved. There were too few on-treatment deaths
from pneumonia to analyze these by GOLD stage.
It is important to note that, although GOLD stage II is
defined by a post-bronchodilator FEV1 > 50% but < 80%
predicted [1], the upper limit for eligibility to the TORCH
study was pre-bronchodilator FEV1  < 60% predicted;
therefore most patients would be expected to fall into the
more severe end of stage II COPD, which was indeed
found to be the case. The majority of patients who were
diagnosed with GOLD stage II COPD had a baseline post-
bronchodilator FEV1 of 50% to < 60% (1360 patients
[64%], while 646 patients [30%] had a FEV1 60% to <
70% and only 122 [6%] had a FEV1 70% to < 80%). This
distribution appears to be similar to the FEV1 % predicted
distribution of stage II COPD patients from a 2005–2007
UK General Practice Research Database population-based
cohort study [GSK Worldwide Epidemiology
(WEUSKOP2207) Final study report, May 2009. Data on
file] and the demographics of the TORCH GOLD stage II
population is also similar to that of the UPLIFT clinical
trial [10]. The majority of patients were also sufficiently
symptomatic, as indicated by high baseline SGRQ total
score, to have presented and been diagnosed with COPD,
most likely as a result of exacerbations.
This analysis provides key information on pharmacother-
apy in patients presenting with milder COPD and such
data are lacking in the current literature and guidelines.
Calverley and colleagues [5] performed a similar post-hoc
analysis of the TRISTAN trial, but divided patients into
FEV1 < 50% predicted and ³ 50% predicted and explored
treatment differences by severity as a continuous variable.
Table 4: Pneumonia adverse events by post-bronchodilator FEV1 % predicted at baseline*
Placebo
(n = 1544)
SAL
(n = 1542)
FP
(n = 1552)
SFC
(n = 1546)
FEV1< 30% predicted
number of patients 215 261 223 246
total treatment exposure (yrs) 378 511 487 546
number of events 28 44 55 89
rate‡ 74 86 113 163
FEV1 30% to < 50% predicted
number of patients 786 750 785 735
total treatment exposure (yrs) 1626 1686 1787 1752
number of events 87 90 171 156
r a t e ‡ 5 45 39 68 9
FEV1 ³ 50% predicted
number of patients 543 531 544 565
total treatment exposure (yrs) 1275 1334 1281 1402
number of events 55 48 74 79
r a t e ‡ 4 33 65 85 6
*Safety population (n = 6184)
‡Rate per thousand treatment years, calculated as (events × 1000/total treatment exposure)
Probability* of pneumonia by 156 weeks by baseline post- bronchodilator FEV1 % predicted Figure 7
Probability* of pneumonia by 156 weeks by baseline 
post-bronchodilator FEV1 % predicted. *Kaplan-Meier 
probability.Respiratory Research 2009, 10:59 http://respiratory-research.com/content/10/1/59
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Lung function was found to improve with active treat-
ment, irrespective of FEV1, with greatest improvements
reported for patients treated with SFC. In contrast to the
findings reported here, only patients with more severe dis-
ease reported significantly reduced exacerbations; how-
ever health status and breathlessness both improved with
active treatment irrespective of FEV1. The present findings
provide further evidence that SFC can be used in patients
with milder COPD.
Inevitably a post-hoc analysis of this type has limitations.
The study was not designed to test for differences between
GOLD stages or differences between treatment arms
within GOLD stages. The numbers of patients in each
stage were different and analyses of treatment subgroups
within stages are underpowered. However, the size of the
study ensured that the baseline characteristics of patients
within each treatment arm was similar in each GOLD
stage. TORCH recruited patients with a pre-bronchodila-
tor FEV1 of < 60% predicted, but a substantial number of
patients fell into GOLD stage II disease, being defined by
spirometric severity based on the post-bronchodilator
value. It is important to note that all had a clinical diagno-
sis of COPD and that the mean total SGRQ in stage II
patients was 45, indicating that they were a symptomatic
group of patients. Finally, we adopted a conservative crite-
rion with respect to study entry based on the former Euro-
pean Respiratory Society reversibility criterion of a change
in FEV1 of less than 10% predicted. This is likely to have
limited our ability to show changes in post-bronchodila-
tor spirometry compared with studies where no reversibil-
ity limitation was present [8,14]. However, this is not
likely to impact on our data for health status or exacerba-
tions, which are unrelated to reversibility status [12].
Conclusion
Our data have clinical implications. Although patients in
GOLD stage IV have worse outcomes such as health status
impairment, higher exacerbation rates and mortality than
did those in GOLD stage II, the latter group are not free
from these important complications. Secondly, treatment
is effective in GOLD stage II as well as in more severe
stages of COPD. Finally, the results presented here suggest
that patients with COPD may obtain important benefits
from SFC combination pharmacotherapy, even at milder
stages of disease.
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